Based on PubMed | Can persistent vision problems be a symptom of endometrial cancer, and what disease-related or treatment-related mechanisms could cause them?

Persistent vision problems are not among the typical first signs of endometrial (uterine) cancer, but they can occur in rare situations due to the cancer itself, immune-related complications, blood-clotting events, spread to the eye or brain, or as side effects of treatment. When vision changes appear in someone with known or suspected endometrial cancer, they should be evaluated promptly because some causes are serious but treatable. ^{[1] [2]}

---

Quick takeaways

• Uncommon but possible: Visual symptoms can arise from endometrial cancer through several mechanisms, most of which are uncommon but clinically important. ^[3]
• Multiple pathways: Mechanisms include immune-mediated retina injury (paraneoplastic retinopathy), hypercoagulability leading to stroke or retinal vessel occlusions, brain or ocular metastases, and treatment toxicities (especially immunotherapy plus chemotherapy). Each mechanism points to different urgent evaluations and treatments. ^{[3] [2] [4]}

---

Typical symptoms vs. atypical vision symptoms

• Typical endometrial cancer symptoms include abnormal vaginal bleeding, postmenopausal spotting, pelvic pain or cramps, and watery/bloody discharge. Vision problems are not listed among the usual presenting symptoms. ^[1]
• That said, people with cancer can develop systemic complications that affect the eyes or brain, so persistent blurred vision, visual field loss, or color/contrast changes warrant medical review. In cancer care, new neurologic or ocular symptoms are treated with caution. ^[1]

---

Disease-related mechanisms that can cause vision problems

1) Paraneoplastic retinopathy (immune-mediated retinal injury)

• Endometrial cancer can rarely trigger the immune system to attack the retina, leading to cancer‑associated retinopathy (CAR). Symptoms include progressive decrease in visual acuity, visual field constriction, photopsias (flashing lights), and sometimes associated eye inflammation. ^[5]
• Case series and reports document CAR in endometrial cancer (including undifferentiated, small‑cell, and clear cell subtypes), with detection of anti‑retinal antibodies (often ~34‑kDa). Ocular findings can precede the cancer diagnosis by months, emphasizing the need to consider paraneoplastic causes in unexplained bilateral vision loss. ^{[6] [7] [3]}

2) Hypercoagulability and thromboembolic events

• Endometrial cancer, particularly higher‑grade or aggressive histologies (e.g., serous, clear cell, carcinosarcoma), is associated with an increased risk of venous thromboembolism and other clotting events. This cancer‑related hypercoagulable state can contribute to stroke or retinal vascular occlusion, causing sudden or persistent vision loss. ^[2]
• In a large cohort of older adults with endometrial cancer, about 8% developed venous thromboembolism around the time of diagnosis or treatment, and these events correlated with worse survival, underscoring clinical significance. Although that study focused on venous events, hypercoagulability reflects a systemic risk that can extend to arterial events (e.g., stroke) influencing vision. ^[2]

3) Metastatic spread to the brain or eye

• Brain metastases from endometrial cancer are uncommon overall, but when present they can cause visual symptoms through occipital lobe or optic pathway involvement. Reports indicate brain involvement is rare but documented within gynecologic oncology cohorts. ^[8]
• Ocular metastases are rare but possible: cases include metastasis to the iris and choroid (uveal tract). Presentations include eye pain, sudden vision loss, retinal detachment, secondary glaucoma, or visible iris nodules. ^{[9] [10]}
• In one report, uterine papillary serous carcinoma metastasized to the choroid and led to severe, painful vision loss, ultimately requiring enucleation of the affected eye. While rare, uveal metastasis should be considered in a person with known uterine cancer who develops acute eye symptoms. ^[10]

---

Treatment-related mechanisms that can affect vision

1) Immune checkpoint inhibitors combined with chemotherapy

• Modern regimens for recurrent or metastatic endometrial cancer often combine carboplatin and paclitaxel with PD‑1/PD‑L1 inhibitors (e.g., dostarlimab, durvalumab). These regimens can cause immune‑related ocular toxicities and neurologic adverse events. ^{[11] [12]}
• Documented ocular toxicities include eye pain, red or swollen eyes, blurred or changed vision, photophobia, watery or dry eyes; and specific inflammatory conditions such as uveitis/iritis, episcleritis, blepharitis, conjunctivitis, tear‑duct stenosis, and even optic neuritis. Vision changes with immunotherapy merit urgent evaluation because steroid treatment can prevent permanent damage. ^{[4] [13]}
• Neurologic immune‑related adverse events (e.g., encephalitis, aseptic meningitis, myasthenia gravis) can involve the visual pathways or optic nerve, sometimes presenting as visual blurring or field loss. Prompt recognition and corticosteroid therapy are often recommended for moderate to severe cases. ^{[13] [14]}

2) Chemotherapy effects

• While carboplatin and paclitaxel are not classically associated with severe chronic ocular toxicity, they can contribute to dry eye, tearing, or transient visual blurring, and rarely more serious effects. Combination therapy with immunotherapy increases the spectrum of potential eye side effects. ^{[11] [12]}

---

How to evaluate persistent vision changes in this setting

• Urgent eye and neurologic assessment: Any persistent or acute visual symptom in someone with cancer warrants prompt evaluation by ophthalmology (ideally a uveitis or retina specialist) and, if indicated, neurology. Early assessment can distinguish inflammatory, vascular, immune, metastatic, or medication‑related causes. ^{[4] [13]}
• Key tests may include:
  • Comprehensive eye exam with slit lamp and dilated funduscopy to look for uveitis, retinal vasculitis, optic disc edema, iris/choroidal masses, or retinal detachment. Findings like uveitis or optic neuritis support immune‑related toxicity; iris/choroidal lesions raise concern for metastasis. ^{[4] [9] [10]}
  • Optical coherence tomography (OCT) and fluorescein angiography if retina is suspected. Electroretinography can help diagnose paraneoplastic retinopathy when the fundus looks relatively normal. ^[5]
  • Brain and orbit MRI with contrast if optic neuropathy, central visual pathway involvement, or brain metastasis is suspected. This is particularly important for acute visual field defects, homonymous hemianopsia, or other neurologic signs. ^[8]
  • Blood work for paraneoplastic anti‑retinal antibodies when CAR is suspected. Positive anti‑retinal antibodies (e.g., ~34‑kDa antigen) support the diagnosis in the right clinical context. ^{[7] [5]}
  • Vascular evaluation if a thromboembolic cause is possible (e.g., carotid/vascular imaging, coagulation profile), especially with sudden vision loss. Cancer‑associated hypercoagulability raises suspicion for stroke or retinal arterial occlusion. ^[2]

---

Management highlights

• Immune‑related ocular toxicity: Often treated with topical or systemic corticosteroids, and sometimes temporary immunotherapy interruption, depending on severity; escalation to additional immunosuppression may be needed for refractory cases. Rapid treatment improves the chance of visual recovery. ^{[4] [13]}
• Paraneoplastic retinopathy: Management can include treating the underlying tumor, immunosuppressive therapy (e.g., steroids, IVIG, plasmapheresis), and in some cases other agents; outcomes vary and early recognition is important. Because retinal damage can progress, timely therapy is critical. ^{[5] [3]}
• Metastatic disease to eye or brain: Options include local radiotherapy, systemic therapy guided by oncologic status, surgical approaches for selected ocular lesions, or palliative measures to reduce pain and preserve function where possible. Treatment is individualized based on extent and histology. ^{[10] [9]}
• Thromboembolic or ischemic events: Managed according to stroke or retinal occlusion protocols, often with antithrombotic therapy and risk-factor modification within the constraints of cancer care. Oncology and neurology/ophthalmology coordination is essential. ^[2]

---

Practical red flags that need same-day attention

• Sudden vision loss in one or both eyes, new visual field defects, or sudden double vision. These can signal stroke, retinal artery occlusion, retinal detachment, or uveal/optic nerve involvement. ^[10]
• Painful red eye with vision decline or marked light sensitivity (photophobia). This can indicate uveitis or optic neuritis, which may require urgent steroids. ^[4]
• New neurologic symptoms with vision change (e.g., severe headache, confusion, weakness). These may reflect central nervous system involvement or immune‑related neurologic toxicity. ^[14]

---

Bottom line

Visual symptoms are not typical first signs of endometrial cancer, but persistent vision problems can occur through several cancer‑related or treatment‑related pathways. Most relevant mechanisms include paraneoplastic retinopathy, hypercoagulability with stroke/retinal occlusion, metastases to the brain or eye, and immune‑related ocular/neurologic toxicity from modern combination regimens. Timely, coordinated evaluation by ophthalmology, neurology, and oncology is important to protect vision and address the underlying cause. ^{[1] [3] [2] [4] [13] [9] [10] [12] [11]}